4.7 Review

Probiotics in Autoimmune and Inflammatory Disorders

期刊

NUTRIENTS
卷 10, 期 10, 页码 -

出版社

MDPI
DOI: 10.3390/nu10101537

关键词

lactobacilli; bifidobacilli; arthritis; inflammatory bowel; microbiome; metabolomics; aryl hydrocarbon reductase; adenosine; histamine; short-chain fatty acid

资金

  1. National Institutes of Health/National Center for Complementary and Integrative Health [R01AT007083]
  2. NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER
  3. National Center for Complementary & Integrative Health [R01AT007083] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI117442] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Probiotics have been used to ameliorate gastrointestinal symptoms since ancient times. Over the past 40 years, probiotics have been shown to impact the immune system, both in vivo and in vitro. This interaction is linked to gut microbes, their polysaccharide antigens, and key metabolites produced by these bacteria. At least four metabolic pathways have been implicated in mechanistic studies of probiotics, based on mechanistic studies in animal models. Microbial-immune system crosstalk has been linked to: short-chain fatty acid production and signaling, tryptophan metabolism and the activation of aryl hydrocarbon receptors, nucleoside signaling in the gut, and activation of the intestinal histamine-2 receptor. Several randomized controlled trials have now shown that microbial modification by probiotics may improve gastrointestinal symptoms and multiorgan inflammation in rheumatoid arthritis, ulcerative colitis, and multiple sclerosis. Future work will need to carefully assess safety issues, selection of optimal strains and combinations, and attempts to prolong the duration of colonization of beneficial microbes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据